1 Multiomics profiling of human plasma and CSF reveals ATN derived 2 networks and highlights causal links in Alzheimer's disease

 $\overline{3}$

 $\overline{4}$ Liu Shi^{a+}, Jin Xu²⁺, Rebecca Green^{c,d,e}, Asger Wretlind', Jan Homann^s, Noel J. Buckley^e, Betty M.

Tijms^h, Stephanie J. B. Vos^l, Christina M. Lill^{g,j,k}, Mara ten Kate^h, Sebastiaan Engelborghs^{l,m}, Kriste Tijms", Stephanie J. B. Vos', Christina M. Lill^{s,j,}", Mara ten Kate", Sebastiaan Engelborghs¹", Kristel

Sleegers^{n,o}, Giovanni B. Frisoni^{p,q}, Anders Wallin', Alberto Lleó^s, Julius Pop^{t,u}, Pablo Martinez-Lage^v Sleegers", Giovanni B. Frisoni",", Anders Wallin', Alberto Lleó', Julius Pop^{o.}, Pablo Martinez-Lage',

Johannes Streffer", Frederik Barkhof^{x,v}, Henrik Zetterberg^{2,aa,bb,cc}, Pieter Jelle Visser^{h,i}, Simon

Lovestone Johannes Streffer^w, Frederik Barkhof^{x, y}, Henrik Zetterberg^{z,aa,bb,cc}, Pieter Jelle Visser^{h,i}, Simon

10 Lovestone^{a,dd}, Lars Bertram^{g,ee}, Alejo J. Nevado-Holgado^a, Petroula Proitsi^{c5}, Cristina Legido-

9 Q Lovestone^{s, La} Lars Bertram^{s, Le}, Alejo J. Nevado-Holgado^a

Quigley^{b, 1*5}

^a Department of Psychiatry, University of Oxford, UK

^b Institute of Pharmaceutical Science, King's College London, Localistic Construc Lovestone^{s, ca}, Lars Bertram^{s, ca}, Alejo J. Nevado-Holgado", Petroula Proitsi^{cs}, Cristina Legido-

Quigley^{b, f*8}

^a Department of Psychiatry, University of Oxford, UK

^b Institute of Pharmaceutical Science, Kin 9 α uigley", $\frac{1}{3}$
 $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{3}$ $\frac{1$

- ^b Institute of Pharmaceutical Science, King's College London, London, UK
- \textdegree Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
- 12 'Institute of Psychiatry, Psychology & Neuroscience, King´s College London, London, UK
13 ^d UK National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre
- London and Maudsley Trust, London, UK
- The London and Maudities, 1989, 2008, 2009
15 The MRC Unit for Lifelong Health & Ageing a
- 16 f Steno Diabetes Center Copenhagen, Gentofte, Denmark
- 17 ^g Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany
- 18 halzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
- 18 "Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
19 ⁱ Department of Psychiatry and Neuropsychology. School for Mental Health and I 19 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, .
20 Alzheimer Centrum Limburg. Maastricht University. Maastricht, the Netherlands
-
- 21 Albert Limburg, Maastricht University, Maastricht, the Netherlands Proceeding of the Netherlands of Epidemiology and Social Medicine, University of Muenster, Muenste
- endamedicine of Mageine, University of Muslim Medicine, Muslim Muslim
13 Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, 13
-
- 23 London, UK l 24 Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of
- 26 m Department of Neurology,
- 27 Brussels, Belgium
- 28 ⁿ Complex Genetics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- 28 "Complex Genetics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
29 ° Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Antv 29 Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Antwerp, I
30 Institute born-Bunges, University of Antwerp, Antwerp, Antwerp, Antwerp, Antwerp, Antwerp,
-
- 30 Belgium
31 ^PUniversity of Geneva, Geneva, Switzerland
- 32 ^q IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- 32 'IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
33 'Institute of Neuroscience and Physiology. Sahlgrenska Academy at Unive 33 'Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg,
34 Gothenburg, Sweden
-
- س
35 Seurology Departme 35 ^S Neurology Department, Hospital Sant Pau, Barcelona, Spain. Centro de Investigación en Red en Red en Red
36 de enfermedades neurodegenerativas (CIBERNED).
-
- 37 t University Hospital of Lausanne, Lausanne, Switzerland
- 37 'University Hospital of Lausanne, Lausanne, Switzerland
38 ^u Geriatric Psychiatry. Department of Mental Health and 38 "Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva university Hospitals,
39 Geneva. Switzerland
-
- 39 Geneva, Switzerland
40 Y CITA-Alzheimer Foundation, San Sebastian, Spain
- 40 °CITA-AIzheimer Foundation, San Sebastian, Spain
41 °° AC Immune SA, Lausanne, Switzerland, formerly . 42 actually conduct the Sa, Lausanne, Switzerland, formerly January January January January January Section at
42 actually conduct
-
- 42 study conduct x 43 Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, The
-
- 44 Netherland
45 ^y Queen Square Institute of Neurology and Centre for Medical Image Computing, University College
46 London, UK
- 47 ² Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- z 47 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden aa ^{aa} Department of Psychiatry and Neurochemistry, Institute of Neuros
49 Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- $\frac{1}{2}$ Sahigara Academy, University of Gothenburg, Mölndal, Swedenburg, Mölndal, Swedenburg, Mölndal, Swedenburg, Mö

bb UK Dementia Research Institute at UCL, London, United Kingdom
51 ^{cc} Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
52 ^{dd} Janssen Medical (UK), High Wycombe, UK

-
- 53 ^{ee} Department of Psychology, University of Oslo, Oslo, Norway
54
-
- 55
- 55
- 57
-
- 58 § Senior authors with
59 § Senior authors with
59 *correspondence:
60 Cristina Legido-Quigley
61 Abstract (150 words lin
- ^{*}correspondence:
60 Cristina Legido-Quigley: <u>cristina legido qu</u>
61 **Abstract (150 words limit)**
63 **INTRODUCTION**: This study employed a 61 Cristina Legion-Quigley: cristina.legion-quigley: cristina.legion-quigley.
...
-

60 Cristina Legido-Qui
61
62 **Abstract (150 word**
63 **INTRODUCTION**: T

²
63 INTRODUCTION: This stude
64 explore molecular signatures framework, MCI conversion explore molecular signatures in blood and CSF, the Amyloid/Tau/Neurodegeneration [AT(N)]
framework, MCI conversion to AD, and genetic risk for AD.
METHODS: Using the EMIF-AD MBD cohort, we measured 696 proteins in cerebr ϵ explore molecular signatures in blood and CSF, the Amyloid, the Amyloid-Tau ϵ and ϵ

- 65 framework, MCI conversion to AD, and genetic risk for AD.
-
- 67 (n=371), 4001 proteins in plasma (n=972), 611 metabolites in plasma (n=696) and genotyped data in
- (n=371), 4001 proteins in plasma (n=972), 611 metabolites in plasma (n=696) and genotyped data in
whole-blood (7,778,465 autosomal SNPs, n=936). We investigated associations: molecular modules
to AT(N), module hubs with A whole-blood (7,778,465 autosomal SNPs, n=936). We investigated associations: molecular modules
- $\frac{1}{\sqrt{N}}$ to $\frac{1}{\sqrt{N}}$ general $\frac{1}{\sqrt{N}}$ general hubs to $\frac{1}{\sqrt{N$
- 70 conversion and probed for causality with AD using Mendelian Randomization (MR).

71

- 72 Proprotein Convertase Subtilisin/Kexin Type 7 showed weak causal associations with AD, and AD was
- 73 causally associated with Reticulocal 2 and sphing-in) small
- Proprotein Convertase Subtilisin/Kexin Type 7 showed weak causal associations with AD, and AD was
Transmally associated with Reticulocalbin 2 and sphingomyelins.
DISCUSSION: This study reveals multi-omics networks associ 75 highlights AD causal candidates.
76 **Key words**: Alzheimer's disease; multi-omics; AT(N) framework; polygenic risk score; Mendelian
77 randomization; multimodal biomarker
- 75 highlights AD causal candidates.
- 76 Key words: Alzheimer's disease; multi-omics; AT(N) framework; polygenic risk score; Mendelian
77 randomization; multimodal biomarker
78
- 77 randomization; multimodal biomarker
-

79

87 rate of disease progression.

80 Alzheimer's dise
79 1. International State
82 1. International State
83 1. Internated to also 80 Alzheimer's disease (AD) is characterised by the presence of β-amyloid (Aβ) containing plaques, and 81 neurofibrillary tangles composed of modified tau protein together with the progressive loss of 82 synapses and neurons [1]. The National Institute on Aging and Alzheimer's Association (NIA-AA) have \mathcal{P} proposed to classify the based on biomarkers of amyloid pathology (A), tau pathology (A), and 84 84 neurodegeneration (N) (the ATN framework) [2]. Yet, despite their diagnostic utility, these three 85 85 markers reflect only a portion of the complex pathophysiology of AD. In prodromal stages, the 86 interplay between AT(N) changes, genetic factors and peripheral molecular changes may affect the

88 88 Conducting unbiased and high-throughput omics-based research in biological fluids and human brain 89 tissues provides a data-driven approach to identify the many processes involved in AD pathogenesis 90 and to prioritize links to relevant clinical and neuropathological traits. For example, an increasing 91 $\frac{1}{2}$ number of protein $\frac{1}{2}$, including ours $\frac{1}{2}$, have identified AD pathophysical AD p 92 pathways related to immune response and inflammation, oxidative stress, energy metabolism and $\frac{1}{2}$ mitochondrial function. Metabolomics studies have also identified such pathways related to $\frac{1}{2}$ 94 11]. A combination of omics, also called multi-omics or deep phenotyping studies, provides an 95 opportunity to explore the molecular interplay with both genotypic and phenotypic variability in AD, 96 96 bringing in new findings and uncovering novel pathways. Finally, causal inferences approaches allow 97 to scrutinize the causal relationship between molecular markers and AD, highlighting potential $\mathcal{L}_{\mathcal{S}}$ interventional targets. Therefore, in this study, we conduct multi-omic analyses with four 99 modalities (cerebrospinal fluid [CSF] proteomics, plasma proteomics, plasma metabolomics and 100 whole blood genetics) from the EMIF-AD MBD study, followed by Mendelian Randomization (MR)

102 We have four objection 103 signatures were asset $\frac{1}{2}$ we wanted to test if $\frac{1}{2}$ if proteins: Fig. 103 signatures were associated with AD endophenotypes including amyloid, CSF total tau (T-tau), CSF

104 104 phosphorylated tau (P-tau), white matter hyperintensity volume, CSF YKL-40, mini mental state 105 examination (MMSE) score, and mild cognitive impairment (MCI) conversion. Secondly, we wanted 106 to investigate the associations between molecular signatures and molecular hubs (main molecules 107 10^{7} driving associations) with APOE4 generypes and AD polygenic risk scores (PAS). This applications 108 to query our findings in prodromal AD by extracting and integrating hub molecules in MCI individuals $\frac{1}{\sqrt{2}}$ by computing a network for $\frac{1}{\sqrt{2}}$ converters versus non-converters. Finally, MRI converters versus non-converters versus non-converters. Finally, MRI converters versus non-converters. Finally, MRI conve 110 analyses interrogated the causal relationship between hub molecules and AD.

113 **2.1. Particip**
114 The EMIF-AI
115 disease (EM 114 The EMIF-AD MBD study is part of the European Medical Information Fr
115 disease (EMIF; <u>http://www.emif.eu/emif-ad-2/</u>); a public-private partner
116 Innovative Medicines Initiative (IMI). The design of the EMIF-AD MB 114 The EMIF-AD MBD study is part of the European Medical Information Framework for Alzheimer's 115 disease (EMIF) disease (EMIF) disease partnership funded through the partnership funded throu 116 Innovative Medicines Initiative (IMI). The design of the EMIF-AD MBD study has been described 1177 previously [12]. Briefly, 1221 samples from three groups of people (cognitively normal controls [CTL], 118 Mai and AD) were chosen from pre-existing cohorts with the goal of including samples from people s 119 119 with pathology as well as those without. All participating centres have agreed to share data as participating 120 $\frac{1}{2}$

121 General clinical and demographic information were available for all subjects (including APOE ϵ 4 122 genotype data). Furthermore, each participant had a measure of brain amyloid load, using either CSF 123 Aβ or amyloid positron emission tomography (PET) imaging. CSF T-tau and P-tau analysis data were 124 available for over 90% of the subjects. We used CSF (or where \mathcal{A}) and \mathcal{A} 125 P-tau 181 as "T" and CSF T-tau as "N" to define the AT(N) framework. The classification of the status 126 (abnormal/normal) of amyloid, P-tau and T-tau has been described previously [12]. We 127 dichotomized these biomarkers as normal or abnormal and categorized them into four groups: no

137 CSF proteomics

128

138 We used tandem mass tag (TMT) technique to measure proteins in CSF. More details can be found in

137 CSF proteomics
138 We used tandem mass tag (TMT) technique to measure proteins in CSF. More d
139 [13]. We imputed proteins using K-nearest neighbour (K=10) and removed $\frac{1}{2}$ imputed proteins using K-nearest neighbour (K=10) and removed any missing $\frac{1}{2}$ 140 leading to a total of 696 proteins in 371 samples for further analysis.

141 Plasma proteomics

142 We used the SOMAscan assay platform (SomaLogic Inc.) to measure proteins in plasma. SOMAscan 143 143 is an appendix dassed assay allowing for the simultaneous measurement and quantification of large 144 number of proteins. Here we measured 4001 proteins in 972 individuals. The details have been 145 described previously [14].

146 Plasma metabolomics

147 We measured plasma metabolites using Metabolon platform (Metabolon Inc.). Metabolites with 148 more than 70% missing were excluded and we imputed the missing metabolites using K-nearest 149 neighbour (K=10), resulting in 611 metabolites in 696 subjects for further analysis. More details can 150 be found in [11].

151 Single nucleotide polymorphism (SNP) genotyping

152 152 and 152 account bioinformatic workflows can bioinformatic workflows can be subsequent b $\frac{1}{2}$ found in $\frac{1}{2}$ for general of 936 DNA samples were sent for general using u 154 154 the Infinitum Global Screening Array (GSA) with Shared Custom Content (Infinitum Inc.). After quality 155 control (ζ -) and imputation, a total of 7,778,465 autosomal SNPs with minor allele frequency (MAF) 156 \geq 156 were retained in 898 individuals of European ancestry for downstrain analyses and generic 157 157 principal components (PCs) were computed [15].

159 All statistical analyses
160 characteristics across th
161 of variance (ANOVA) an 159 All statistical analyses were completed using R (version 4.1.2). To compare baseline cohort 160 characteristics across three different diagnostic groups (CTL, MCI and AD), we used one-way analysis

161 of variance (ANOVA) and chi-square tests to compare continuous and binary variables, respectively.

162 Weighted Gene Correlation Network Analysis (WGCNA)

163 163 We used the R package WGCNA [16] to construct a weighted and unsigned co-expression network 164 for each individual omics layer. This clustering method is based on calculating correlations between $\frac{1}{2}$ paired variables. The resulting modules of co-expressed analytes were used to calculate were used to calculate to calculate $\frac{1}{2}$ 166 module eigenprotein/eigenmetabolite metrics. The eigenprotein/eigenmetabolite-based 167 connectivity (kME) value was used to represent the strength of an analyte's correlation with the 168 module. Analytes with high intramodular kME in the top 90th percentile within a module were 169 considered as hub proteins/metabolites.

170 The correlations between eigenprotein/eigenmetabolite and AD endophenotypes were calculated 171 using Spearman's correlation, the p values were corrected with false discovery rate (FDR) and 172 corrected p values are presented in a heat map. Furthermore, we used one way ANOVA test to 173 assess pairwise difference of eigenprotein/eigenmetabolite among different AT(N) framework.

174 Pathway enrichment analysis

175 software 175 Protein pathway enrichment analysis was performed using WebGestalt software $\frac{1}{\sqrt{1+\beta}}$ organisation a module within a module within a module were assembled into a "protein list" list" a module within a module with 177 and all proteins measured were used as "background". This enrichment analysis was performed on 178 178 the KEGG database. Metabolite enrichment analysis was performed using the hypergeometric test. 179 The original 60 sub-pathways pre-defined by Metabolon based on the KEGG database were 180 employed as reference further performed cell type enrichment analysis for α \overline{a}

182 AD polygenic risk score (PRS) calculation

183 The genome-wide association study summary statistics from Kunkle et al. [18] (N=63,926; 21,982 AD 184 184 clinically ascertained cases, $41,944$ controls) were used as the reference data. PRS were constructed 185 using PRSice-2 [19], with and without SNPs in the APOE region (chr 19, GRCh37 coordinates $\frac{1}{2}$ to 45912079 to 45912079 to 45912079 to 459120 to 459120 to p-value thresholds (PT), previously previo 187 recommended for PRS including and excluding the APOE region: $5x10^{-8}$ (APOE region included) and 188 0.1 (APOE region excluded) [21]. SNPs in linkage disequilibrium (r2>0.001 within a 250kb window) 189 were clumped, retaining the SNP with the lowest p -value.

190 Association of AD PRS and AT(N) with modules and hubs

191 191 We used linear regression analyses to investigate the association of AD PRS (as predictor) with 192 eigenprotein/eigenprotein/eigenmetabolite of AT(N) framework-related modules and hub proteins/metabolites and hub proteins/metabolites and hub proteins/metabolites and hub proteins/metabolites and hub proteins/metab 193 (with kME varying from top 90th percentile to top 98th percentile) in these modules, adjusting for 194 $\frac{1}{2}$ sex, and generic population stratification str 195 regression analyses to explore the association of AT(N) markers (as binary outcome) with hubs, 196 adjusting for sex, age and APOE ε4 genotype.

197 Partial correlation network

198 We used age, sex, APOE genotype, AD PRS ($P_T = 0.1$, APOE region excluded) and all hub 199 proteins/metabolites (with kME in the top 90th percentile) as input features for the graphical LASSO 200 algorithm and extended Bayesian information criterion to determine the model complexity for MCI 201 201 conversion using the R package `huge´ [23]. Data were auto-scaled prior to model-fitting. Partial 202 correlation network of selected metabolites, proteins and genetic variables was computed and 203 visualized with R package 'qgraph'.

204 Mendelian randomization

 205 We finally investigated whether any of the A/T /N hubs correlating with MCI conversion status were 206 causally linked to AD, by performing bi-directional two-sample Mendelian Randomization (MR) 207 analyses implemented in the "TwoSampleMR" R package [24] and the MendelianRandomization 208 package for an alyses for both single cis instrument MR and multiple (cis) instrument MR and multiple (cis) 210 findings.
211
212 3. Results

210 findings.

213 3.1. Subje
214 Table 1 sh
215 the differe 214 Table 1 shows the demographics
215 the difference in sample siz
216 the distribution of sex acro 215 the difference in sample size for each omics layer analysis, no significant difference was observed in
216 the distribution of sex across different diagnostic groups. However, the CTL group was younger and
217 had a lo \mathcal{L} the difference in sample size for each omic size for each omics layer analysis, no significant difference was observed in \mathcal{L} the distribution of sex across different diagnostic groups. However, the CTL group was younger and 217 had a lower proportion of APOE ε4 carriers compared with the MCI and AD groups. Furthermore, the 218 CTL participants had longer education and higher MMSE score. In terms of AD pathology markers, 219 the ratio of abnormality of amyloid, P-tau and T-tau in AD and MCI individuals was, as expected, 220 significantly higher than in controls.

222

endophenotypes
224 We first performed a clustering analysis of the CSF proteome using WGCNA. We found four modules
225 (M) of co-expressed proteins. We ranked modules based on size from largest (M1 turquoise; n= 526
226 an 224 We first performe
225 (M) of co-expresse
226 proteins) to small 224 Me first performed a clustering analysis of the CSF protein \mathcal{C} 225 (M) of co-expressed proteins. We ranked modules based on size from largest (M1 turquoise; n= 526 227 biological significance of proteins in each module and found that three modules (M1 turquoise, M2
228 blue and M4 yellow modules) were enriched with various pathways after FDR correction (Figure 2B).
229 When checking 227 biological significance of proteins in each module and found that three modules (M1 turquoise, M2 229 blue and M4 yellow modules were enriched with endothelial
230 cells. Furthermore, M1 turquoise module was enriched with oligodendrocytes, neurons and
231 astrocytes. M2 blue and M4 yellow modules were enriched with mic 229 When checking cell type enrichment, we found that all four modules were enriched with endothelial 230 cells. Furthermore, M1 turquoise module was enriched with oligodendrocytes, neurons and α

232 We then assessed the module correlations to AD endophenotypes. We used amyloid-β
233 tau levels as a biomarker of tau ("T"), CSF T-tau as biomarkers of neurodegeneration
234 matter hyperintensity (WMH) volume as a bi 232 We then assessed the module correlations to AD endophenotypes. We used amyloid-β as "A", CSF P-233 tau levels as a biomarker of tau ("T"), CSF T-tau as biomarkers of neurodegeneration ("N"), white 234 matter hyperintensity (WMH) volume as a biomarker for variable burden (\sqrt{M}), CSF YKL-400 236 and three (M1, M2 and M3) modules were significantly associated with "T" and "N", respectively
237 after FDR correction. Furthermore, three (M1, M2 and M4) modules were associated with "I". None
238 of the modules were 236 and M3) modules were significantly associated with "T" and "N", respectively associated w 237 after FDR correction. Furthermore, three (M1, M2 and M4) modules were associated with "I". None 238 of the modules were correlated with "A", "V", "C" or MCI conversion.

239 We used the same approach to analyse plasma proteomics and metabolomics data. We obtained 240 M4 and M8) had positive correlations with "A", "T" and "N". One (M3) and four (M1, M3, M8 and
242 M9) modules were associated with "V" and "I", respectively. In comparison, most plasma modules
243 were associated with "C" 241 M4 and M8) had positive correlations with "A", "T" and "N". One (M3) and four (M1, M3, M8 and 242 M9) modules were associated with "V" and "I", respectively. In comparison, most plasma modules 243 were associated with "C" and MCI conversion. Furthermore, such associations were in concordance with AT(N) markers correlations. For example, M2, M3, M4 and M8 modules were positively 245 associated with "A", "T" and "N" but were negatively correlated with MMSE score. Furthermore,

246 they were increased in MCI converters (n=103) compared with MCI non-converters (n=223) (Figure

247 248 modules (M2, M3, M4 and M8) and found that three of them were enriched with various pathways,
249 such as cytokine-cytokine receptor interaction and metabolic pathways (Figure 2D).
250 For plasma metabolomics, we obtai 248 modules (M2, M3, M4 and M3) and found that the enriched with various pathways, 250 For plasma metabolomics, we obtained seven modules (Figure 2E), among which
251 negatively associated with "A", "T" and "N" and M3 module was positively associated with "A", "T" and "N" and M3 modules were associated w 251 For plasma metabolomics, we obtained seven module (Figure 2E), and in the seven module was
252 Furthermore, one (M1) and two (M1 and M4) modules were associated with "V" and "I",
253 Furthermore, one (M1) and two (M1 a 251 negatively associated with "A", "T" and "N" and M3 module was positively associated with "N". 252 Furthermore, one (M1) and two (M1 and M4) models with models with "V" and "I", 253 respectively. Two (M3 and M4) and four (M4) ms) modules with μ modules with associated with μ 254 and MCI conversion respectively. Furthermore, such associations were in concordance with AT(N) 2555 matrix correlations. We further investigated the biological significance of metabolites in $\mathcal{N}(N)$ 257 2F).
258
259 3.3 Correlation of individual omics modules with the AT(N) framework
268 and found that they were enriched in line pathways (Figure 1)

258
259 **3.3 0**
260 We 260 We dichotomized AT(N) biomarkers as normal or abnormal and catego
261 four groups: A-T-N- (no pathology), A+TN- (amyloid pathology), A+TN+ (
262 TN+ (SNAP). We then assessed the expression of each module eigenpro 260 We dichotomize as normal or abnormal and categorized individuals individuals individuals individuals in 261 four groups: A-T-N- (no pathology), A+TN- (amyloid pathology), A+TN+ (Alzheimer pathology) and A-262 TN+ (SNAP). We then assessed the expression of each module eigenprotein/eigenmetabolite across 263 different ATN groups. For CSF protein modules, we found that three modules (M1 turquoise, M2 264 blue and M4 yellow) showed a significant difference across ATN profiles from one-way ANOVA test 265 266 3D-G, adapted from [26]) and three plasma metabolites modules (M4 yellow, M5 green and M3 brown, Figure 3H-J) showed a significant difference across ATN profiles. 267 brown, Figure 3H-J) showed a significant difference across ATN profiles.
268
3.4 Association between AT(N) framework-related modules and AD PRS

268
269 brown, S. 4 Association between AT(N) framework-related modules and AD PR
269 brown, Figure and AD profiles. 269 3.4 Association between AT(N) framework-related modules and AD PRS

270 270 We firstly selected \overline{N} framework-relation modules from each individual omics for further analysis. 271 As a result, we selected three CSF protein modules (M2 turquoise, M2 blue and M4 μ yellow), four 272 plasma protein modules (M2 blue, M3 brown, M4 yellow and M8 pink) and three plasma metabolite 273 273 modules (M3 brown, M4 years). We then σ except the analysed the correlations between these 274 ten modules as well as between these modules and AD PRS. When analysing associations between 275 modules, we found that the metabolite M5 green module was negatively correlated with the metabolite \sim 276 plasma protein modules (M3 bink). Additionally, a negative correlation was negative correl 277 observed between metabolite M3 brown module and plasma protein M8 pink module. In contrast, a 278 positive correlation was observed between metabolite M4 yellow module and plasma protein M4 279 yellow module as well as between metabolite M3 brown module and CSF protein M4 yellow module. 280 In addition, CSF protein M4 years module was positively associated with plasma protein M3 brown

282 Mhen analysing the associations
283 protein modules were significant
284 (M2 blue and M4 yellow) were p When analysing the associations between these modules and AD PRS, we found that only plasma 283 protein modules were significantly associated with AD PRS. In detail, two plasma protein modules 284 (M2 blue and M4 yellow) were positively associated with PRS (APOE region included and excluded) 285 at P_T=0.1. Additionally, M2 blue module was significantly associated with PRS at 5x10⁸ threshold

287
288

286 with *APOE* gene region included (Fi**gure 3K, Table S4).**
287 **3.5 Association of hub proteins/metabolites with AT(I)**
289 We selected hub proteins/metabolites within AT(N) 1 289 We selected hub proteins/metabolites within AT(N) framework-related mod
290 association between these hub proteins/metabolites (with kME varying from
291 top 98th percentile, **Table S5**), as well as the association of We selected hub proteins/metabolites within AT(N) framework-related modules and analysed the 290 association between these hub proteins/metabolites (with kME varying from top 90th percentile t 292 markers and AD PRS. When checking the associations between hub metabolites and proteins, we
293 found that there was a strong correlation between metabolites and plasma proteins. In detail, five
294 metabolites (four p 292 markers and AD PRS. When checking the associations between hub metabolites and proteins, we have \mathcal{N} 293 found that there was a strong correlation between metabolites and plasma proteins. In detail, fixed plasma protei 294 metabolites (four phosphatid) correlations (PEs) and one LysoPE) correlated with most hub

295 295 proteins after controlling for multiple testing. Two metabolites (sphingomyelins [SM] d40:2 and 296 d41:2) in M3 brown module with correlated with proteins in plasma M8 pink module and CSF M4 297 yellow module. In contrast, relatively week correlations were observed between CSF and plasma 298

299 We also investigated the associated for a series included and excluded (Table S6).
201 positively associated with AD P6. 299 We also investigated the association of these proteins/metabolites with AD PRS (APOE region 301 positively associated with AD PRS both at $P_T = 5 \times 10^{-8}$ (*APOE* region included) and $P_T = 0.1$ (*APOE* region included and excluded). Similar trend was also observed for most proteins in M4 yellow module, with only 301 positively associated with AD PRS both at $P_T=5x10^{-8}$ (APOE region included) and $P_T=0.1$ (APOE region 302 included and excluded). Similar trend was also observed for most proteins in M4 yellow module, 303 with only six proteins being positively associated with AD PRS at $P_T=5x10^8$ (APOE region included), 304 whereas most proteins, except for three, were associated with the $P_T=0.1$ AD PRS (with APOE and 305 without *APOE*) (Figure 4A). For hub metabolites, three SMs in M3 brown module and three PEs in
306 M5 green module were associated with AD PRS $(P_T=5x10^8)$ with and without *APOE* region
307 respectively. However, su 306 M5 green module were associated with AD PRS $(P_T=5x10^{-8})$ with and without APOE region 308 associations were observed between CSF hub proteins and AD PRS.

308 associations were observed between CSF hub proteins and AD PRS.
309 When investigating the association of hub proteins and metabolites with AT(N) markers, we found
310 that most CSF and plasma hub proteins were positiv $\overline{3}$ when investigating the association of hub proteins and metabolites with AT(N) markers, we found metabolites with AT(N) markers, we found metabolites with AT(N) markers, we found metabolites with AT(N) markers, we $\frac{1}{3}$ that most CSF and plasma hub proteins were positively associated with amyloid, P-tau and T-tau and T- $\frac{1}{2}$ after FDR correction. In contrast, hub metabolites were negatively associated with amyloid, P-tau 312

313 3.6 Hub molecules integration in MCI conversion
314 Having demonstrated the association of hub proteins/metabolites with AT(N
315 we then sought to find a multimodal signal that might shed insights on MCI 314 Having demonstrated the association of hub prot
315 We then sought to find a multimodal signal that r
316 We first used LASSO algorithm and extended Baye $\frac{1}{2}$ Having demonstrated the association of hub proteins/metabolites with AT(N) markers and AD PRS, and AD P 315 we then sought to find a multimodal signal that might shed insights on MCI conversion. To do this 316 we first used LASS ω_0 algorithm and extended Bayesian information criterion to select features from 317 age, sex, AD PRS ($P_T = 0.1$, APOE region excluded), APOE ϵ 4 genotype and all plasma hub 319 metabolites/proteins (with kME in the top 90th percentile, Table S9) to predict MCI conversion. As a result, AD PRS, APOE ε 4 genotype and several metabolites/proteins were selected from LASSO. Of 319 result, AD PRS, APOE ε4 genotype and several metabolites/proteins were selected from LASSO. Of 320 320 the metabolites/proteins, two SMs, two PEs and one protein (proprotein convertase subtilisin/kexin $\frac{3}{2}$ type $\frac{1}{2}$ correlated with MCI conversion with MCI conversion with MCI conversion with MCI conversion with $\frac{1}{2}$ 3222 four selections were positively associated with MCI conversion including reticulous reticulocal bin 2 323 \mathcal{S} (RCN2) from the blue module, and three proteins from the brown module: ephrin receptor tyrosine: 324 kinase A2 (EFNA2), Collagen alpha-1(XV) chain (COL15A1) and AP-1 complex subunit gamma-like 2 326 (AD-PRS and *APOE* e4 genotype (**Figure 4B**).
327 (3.7 Causal links of hub proteins/metabolites with AD
328 (We finally used a bidirectional two-sample Mendelian randomization to determine whether there

326 AD PRS and *APOE* ε4 genotype (Figure 4B).
327 3.7 Causal links of hub proteins/metabolite
328 We finally used a bidirectional two-sample
329 was evidence for a causal relationship of 328 We finally used a bidirectional two-sample Mendelia
329 was evidence for a causal relationship of MCI conve
330 Alzheimer's disease. Using Wald ratio estimate, we ob 328 We finally used a bidirectional two-sample Mendelian randomization to determine whether there 329 was evidence for a causal relationship of MCI conversion related hub proteins/metabolites with 330 Alzheimer's disease. Using Wald ratio estimate, we observed weak associations between PCSK7 and 331 AD as well as between COL15A1 and AD using data from Sun et al. [27]. In sensitivity analyses, the 332 332 causal relationship between PCSK7 and AD was replicated using summary data from an independent 334 association of PCSK7 with AD came from multiple-cis instrument MR (p<0.001 for IVW, 95% CI = 0.8
335 to 0.9, N $_{SNPs}$ = 4, Figure S4), although this was not the case for COL15A1 (Table S10). Multiple-cis
336 instrumen 334 association of PCSK7 with AD came from multiple-city instrument MR (point M 336 instrument MR robust methods (MR-Egger and Weighted-median MR) and sensitivity analyses
337 estimates for PCSK7 were consistent with Wald ratio estimates in direction and magnitude, and
338 showed no horizontal pleiotr 336 instrument MR robust methods (MR-Egger and Weighted-median MR) and sensitivity analyses 337 estimates for PCSK7 were consistent with Wald ratio estimates in direction and magnitude, and 338 showed no horizontal pleiotropy or evidence of heterogeneity, further supporting the validity of the 340 MR assumptions (Table S21). In reverse MR analysis, in revenues a causa accounting a causal Alzheimer's disease, RCN2 and SM (Table 2, Figure S1-3). Robust methods and sensitivity analyses
341 provided additional suppo 341 provided additional support for such causal effects (Table S10).
342
343 4. Discussion (words:1161)

 342
 343 **4.** Discussion (words:1161). 343 4. Discussion (words:1161)

344 Alzheimer's disease is characterized by non-linear and heterogeneous biological alterations. Multi-345 level biological networks underlie AD pathophysiology, including but not limited to proteostasis 3466 and tau), synaptic homeostasis, inflammatory and immune responses, lipid and energy and energ 347 347 metabolism, and oxidative stress [30]. Therefore, a systems-level approach is needed to fully capture. 348 AD multifaceted pathophysiology. Here we used unbiased and high throughput multi-omics profiling 349 of AD. We applied correlation network analysis to identify modules linked to a variety of AD 350 endophenotypes including "A", "T", "N", "V", "I" and "C". We found that four modules obtained $\frac{1}{3}$ from CSF proteins were associated with at least one pathology matrix $\frac{1}{3}$. $\frac{1}{3}$, \mathcal{S} is the three "I" related modules (M1 turquoise, M2 blue and M4 yellow) and M4 353 were enriched with either microglia or astrocytes, which are key cellular drivers and regulators of α 354 neuroinflammation $\{31\}$, further indicating the consistency between correlation network analysis $\frac{3}{2}$ and cell type enrichment analysis. In addition, of the four modules, three were enriched with various 356 pathways which have been reported being associated with Alzheimer's such as Ras signalling 357 pathway [32], axon guidance [33], cell adhesion molecules (CAMs) [34], and lysosome pathway [35], 358 further demonstrating the relatedness of these proteins with AD.

359 From plasma metabolomics, we found that the M3 brown module was associated with "N" (T-tau) 360 $\begin{array}{c} \begin{array}{ccc} \bullet & \bullet & \bullet & \bullet & \bullet \end{array} \end{array}$ 361 with literature report as the lipids within this module have been reported being associated with 362 cognitive progression [36] and hippocampal atrophy [37]. In addition, M4 yellow module was 363 associated with five AD pathology markers ("A", "T", "N", "I" and "C") and enriched with three 364 pathways including gamma-glutamyl amino acid, plasmalogen, and polyamine metabolism. The 365 $\frac{3}{2}$ findings are also consistent with previous reports showing that these pathways were associated with 366 AD pathogenesis [38] and inflammatory cascade [39].

 3677 Two modules (M2 blue and M4 yellow) from plasma proteimics with AD PRS (both 368 with and without APOE gene) at 0.1 level. Of the two modules, M2 blue module was associated with 369 PRS at $5x10⁻⁸$ thresholds only when PRS included SNPs in the APOE region, indicating that such 370 association may be driven by APOE. Hub proteins in M2 blue module were correlated with PRS at 371 $5x10^{-8}$ thresholds only with SNPs in the *APOE* region included, further indicating that associations 372 may be driven by APOE. For plasma metabolomics, three sphingomyelins (SMs) from M3 brown 373 module were associated PRS ($P_T = 5x10^{-8}$) nominally only when the *APOE* region was included, also 374 indicating APOE gene dependence. This is in line with literature findings that nominal association 375 between SMs and PRS was reported [40].

376 We identified several closely correlated networks for metabolites, proteins, genetic factors, and MCI 377 conversion. Interestingly APOE and MCI conversion status were correlated to PCSK7 and 378 sphingomyelins SMs have been previously associated with cognitive progression in AD [41-43]. 379 Furthermore, the integration of AD PRS showed that phosphatidylethanolamines [44, 45] and EFNA2 $\frac{1}{2}$ were associated to both (MCI converter and AD PRS), with potential as early targets.

381 $\frac{1}{2}$ we finally investigated the causal relationship between A/T/N hubs associated with MCI conversions associated with MCI conversions associated with MCI conversions associated with MCI conversions associated with 382 status and AD. Our MR analyses highlighted a potential weak causal relationship between PCSK7 and 3833 AD which was robust in both single and multiple cis instruments $M_{\rm H}$ and was replicated wa 384 using an independent pQTL dataset. We also found a causal relationship in the opposite direction, 385 whereby AD status is potentially causally linked to RCN2 that has been proposed as a therapeutic 386 386 target for atherizing for μ , μ summ μ , although we didn't have GWA summary data for the SM and 387 PE hubs examined in this study, our MR analyses showed that AD was causally linked to SM levels, as 388 previously shown when NMR data were used [48].

389 389 These findings are of great translational potential, particularly PCSK7 for which studies in Alzheimer's i 390 disease are lacking. This convertase protein is very interesting as it is found in the BACE1 locus region 391 which encompasses several genes (PCSK7, RNF214, BACE1, CEP164) making it a plausible protein 392 activator of downstream amyloid deposition [49].

393 The causal associations from AD to RCN2 and sphingomyelins are also intriguing as both highlight a 394 possible vascular component caused by AD genetic liability, bringing new directionally between 395 vascular disease and dementia. These molecules and their potential causal links to AD suggest novel 396

 3977 There are limitations for our study. First, the population in this study is of European ancestry and 398 mainly included participants who had high ratio of amyloid pathology and APOE ε4 carriers. 399 $\frac{3}{2}$ 99 Therefore, they are not necessarily representative of the broader community. Validation in 400 independent cohorts and particularly in other ethnic groups and community-based populations are

402 $\frac{1}{2}$ despite this, our study is the largest study we are aware of to report multi-omics relating to AD 403 $\frac{1}{2}$ end $\frac{1}{2}$ framework. Our findings of $\frac{1}{2}$ framework. Our findings into changes in the changes into changes in the changes of $\frac{1}{2}$ $\frac{1}{2}$ in the AT(N) framework and AD endophenotypes, the AT(N) framework and AD endophenotypes, the AT(N) framework and AD PRS. 405 \mathcal{F} and notinated causal proteins/metabolites may be tractable targets for \mathcal{F} 406 pathology. Furthermore, they may represent promising drug targets in the early stages of AD.

408

 $\frac{1}{\sqrt{2}}$

409 SL is named as an i
410 Kings College Londo
411 Optum labs, Mercl 409 SL is named as an inventor on biomarker intellectual property protected by Proteome Sciences and $\frac{1}{2}$ kings College London unrelated to the past five years has advised for past five years has advised for past five years has advised for $\frac{1}{2}$ 411 Optum labs, Merck, SomaLogic and been the recipient of funding from AstraZeneca and other 412 companies via the IMI funding scheme. HZ has served at scientific advisory boards and/or as a 413 consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, 414 Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, $\frac{1}{2}$ roches, samulting, Siemens Healthineers, Triplet Therapeutics, and Wave, given lectures in 416 symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of

417 Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator \mathcal{A}_1 . Also provide submitted work). AL has served at scientific advisory boards of Fujirebio Europe, Eli \mathcal{H} is the inventor of and Otsuka and Otsuka and is the inventor of a patent on synaptic markers in CSF (all \mathcal{H} 420 \mathcal{A} and this study). JP has served at served at scientific advisory boards of Fujirebio Europe, Eli Lilly and 421 Nestlé Institute of Health Sciences, all unrelated to this study. SE has received unrestricted research $\frac{1}{2}$ grants from Janssen Pharmaceutica and $\frac{1}{2}$ neurosciences and has served at s 423 boards of Biogen, Eisai, icometrix, Novartis, Nutricia / Danone, Pfizer, Roche, all unrelated to this 424 study. FB is a steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. $\frac{1}{2}$ Consultant for Roche, IXICO, Jansen, Combines with Merck, IXICO, Ja 426 Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD, all $\frac{1}{2}$

429 This research was comments of the Innovative Med
431 Fermowork Program
432 Fermowork Program 429 ± 29 This research was conducted as part of the EMIF-AD MBD project which has received support from \sim 430 the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no 115372, 431 resources of which are composed of financial contribution from the European Union's Seventh $\frac{1}{2}$ Framework Programme (FP7/2007-2013) and EFPIA companies in and EFRICA contribution. The DESCRIP $\frac{1}{2}$ 333 study was funded by the European Commission within the 5th framework program (QLRT-2001-434 \mathcal{A}_1 , \mathcal{A}_2 , the EDAR study was funded by the European Commission within the 5th framework program 435 (contract # 37670). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant 436 numbers 41120 , 41207 and 415005 , R is a senior clinical investigator of the Flemin Research \mathcal{A} Foundation (FWO). The San Sebastian GaP study is particular funded by the Department of Health of Heal 438 $\frac{3}{8}$ 4399 contribution of the personnel of the Genomic Service \mathcal{L} at the VIB-U Antwerp Center for \mathcal{L} \mathcal{A} and \mathcal{A} at \mathcal{A} and \mathcal{A} is funded in part by the University of Antwerp 441 Research Fund. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council

442 442 (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical $\frac{4}{3}$ Research (#ALFGBG-720003), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-444 2016862), and the UK Dementia Research Institute at UCL. FB is supported by the NIHR biomedical 445 $\frac{4}{5}$ research centre at UCLH. La is funded by the Virtual Brain Cloud from European commission (grant 446 no. H2020-SC1-DTH-2018-1). R.G. was supported by the National Institute for Health Research (NIHR) 447 $\frac{1}{2}$ Biomedical Research Centre at South London and Maudsley NHS $\frac{1}{2}$ College and King's College 448 London. This paper represents independent research part-funded by the National Institute for 449 Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation $\frac{1}{\sqrt{2}}$ Trust and King's College London. The views expressed are those of the author(s) and not necessarily and not $\frac{1}{\sqrt{2}}$ the NHS, the NHS, the NIHR or the Department of Health and Social Care. $\frac{1}{\sqrt{2}}$ and $\frac{1}{\sqrt{2}}$ $\frac{1}{2}$ For the support $\frac{1}{2}$ (grant no. $\frac{1}{2}$ -2024-2020).

- 454 Written informed
455 medical ethics cor
456 **Data Availability** $\frac{454}{100}$ Written informed consent was obtained from all participants before in the study. The s
- 455 medical ethics committee at each site approved the study.

- 457 The datasets ger
458 Catalogue via sul
459 each parent coho $\frac{457}{\sqrt{100}}$ The datasets generated and analysed during the current study are available from the EMIF-AD
- $\frac{1}{\sqrt{2}}$ catalogue via submitted research proposals which have to be approximately the data-owners from $\frac{1}{\sqrt{2}}$
- 459 each parent cohort.

-
- 462 2. Jack, C.R., Jr., et al., NIA-AA Research Framework: Toward a biological definition of
463 *Alzheimer's disease.* Alzheimers Dement, 2018. **14**(4): p. 535-562.
-

461 1. Kno
462 2. Jack
463 *Alzh*
464 3. John
465 *cere*
466 *astr* 1. Knopman, D.S., et al., *Alzheimer disease*. Nat Rev Dis Primers, 2021. 7(1): p. 33.

162 2. Jack, C.R., Jr., et al., *NIA-AA Research Framework: Toward a biological definition*

163 *Alzheimer's disease.* Alzheimers Dem Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-562.

464 3. Johnson, E.C.B., et al., *Large-scale proteomic analysis of Alzheimer*

465 *cerebrospinal fluid reveals early changes in energy metabolism ass

466* 464 3. Johnson, E.C.B., et al., Large-scale proteomic analysis of Alzheimer's disease brain and
465 eerebrospinal fluid reveals early changes in energy metabolism associated with microc 465 cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and

- 466 astrocyte activation. Nat Med, 2020. **26**(5): p. 769-780.
467 4. Higginbotham, L., et al., Integrated proteomics reveals *k*
468 biomarkers in asymptomatic and symptomatic Alzheime
- 467 4. Higginbotham, L., et al., Integrated proteomics reveals brain-based cerebrospinal fluid
468 biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci Adv, 2020. 6(43). 468 biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci Adv, 2020. 6(43).

19 Alzheimers Dement, 2021. 1₉
19 Alzheimers Dement, 2021. 17
19 Alzheimers Dement, 2021. 17

570 49. Damotte, V., et al., *Plasma amyloid β levels are driven by genetic variants near APOE, BACE1,*
571 *APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.*

- 571 APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.
572 Alzheimers Dement, 2021. 17(10): p. 1663-1674.
- 573
574
574

573

577 variables, respectively. Percentage of cases is shown in brackets for male sex, APOE ε4 carriers and binary
578 the abnormality of amyloid. P-tau and T-tau. 578 the abnormality of amyloid, P-tau and T-tau.

CTL, cognitively normal controls; MCl, mild cognitive impairment; AD, Alzheimer's disease; CSF,

T-tau + N (%) 641 45 (19) 177 (65) 107 (79) <0.001
L, cognitively normal controls; MCl, mild cognitive impairment; AD, Alzheimer's disease
rebrospinal fluid; SD, standard deviation; MMSE, mini mental state examination; +, L, cognitively normal controls; MCl, mild cognitive impairment; AD, Alzheimer's disease
rebrospinal fluid; SD, standard deviation; MMSE, mini mental state examination; +, abnorr
cau, phosphorylated tau; T-tau, total tau. 580 cerebrospinal fluid: SD, standard deviation: MMSF, mini mental state examination: +, abnormality: 581 cerebrospinal fluid; SD, standard deviation; MMSE, mini mental state enamination; +, abnormality; +, above

581 P-tau, phosphorylated tau; T-tau, total tau.

SM 58 [29] 1.28 (0.87 - 1.30) 0.212** 21 0.14 (0.03 - 0.09) 0.344

*The Wald ratio estimate and inverse variance weighting (IVW) estimate were used for MR analyses with a

single and multiple SNPs, respectively.

** Cochr SM 58 [29] 1.28 (0.87 - 1.89) 0.212

*The Wald ratio estimate and inverse variance weighting (IVW) estimate were used for MR analyses with a

single and multiple SNPs, respectively.

** Cochran's Q p<0.001

***there was s 585 single and multiple SNPs, respectively.
586 ** Cochran's Q p<0.001
587 ***there was significant heterogeneity even after removing APOE (Cochran's Q p<0.05).
588

586 stand multiple and multiple and multiple SNP state of the SNP state SNPs and multiple SNPS and multiple SNP
588 standard multiple SNPS snPSNP snPSNPS and multiple SNPS snPSNPS and multiple SNPS snPSNPS snPSNPS and mult 586 ** Cochran's Q p<0.001 587 ***there was significant heterogeneity even after removing APOE (Cochran's Q p<0.05).
588
.

589

591 impairment; AD, Alzheimer's disease; Aβ, β-amyloid; CSF, cerebrospinal fluid; A, amyloid pathology;
592 T, tau pathology; N, neurodegeneration; PRS, polygenic risk score; MR, mendelian randomization.

590 Figure 1. Flow
591 impairment; AD
592 T, tau pathology
593 Figure 2. Indiv
594 correlation netv
595 modules; (B) Er 591 impairment; AD, Alzheimer's disease; Aβ, β-amyloid; CSF, cerebrospinal fluid; A, amyloid pathology;
592 T, tau pathology; N, neurodegeneration; PRS, polygenic risk score; MR, mendelian randomization.
593 **Figure 2. I** 592 T, tau pathology; N, neurodegeneration; PRS, polygenic risk score; MR, mendelian randomization. 594 correlation network analysis (WGCNA) of the CSF proteomics and cell type enrichment analysis of modules; (B) Enriched KEGG pathways of three modules in CSF proteins; (C) WGCNA of plasma proteomics; (D) Enriched KEGG p 594 correlation network analysis (WGCNA) of the CSF proteomics and cell type enrichment analysis of
595 modules; (B) Enriched KEGG pathways of three modules in CSF proteins; (C) WGCNA of plasma 596 proteomics; (D) Enriched KEGG pathways of three modules in plasma proteins; (E) WGCNA of plasma 597 metabolomics; (F) Enriched KEGG pathways of two modules in plasma metabolites. * and ** denote 598 significant correlations $p < 0.05$ and $p < 0.001$ after false discovery rate (FDR) correction respectively; 599 CSF, cerebrospinal fluid; "A", amyloid; "T", tau; "N", neurodegeneration; "V", vascular; "I", 600 inflammation; "C", cognition; +, abnormality; P-tau, phosphorylated tau; T-tau, total tau; WMH, 601 white matter hyperintensity; MMSE, mini mental state examination; MCI, mild cognitive impairment. 601 white matter hyperintensity; MMSE, mini mental state examination; MCI, mild cognitive impairment.

603 of the AT(N) framework with (A-C) three CSF protein modules, (D-G) four plasma protein modules, (H-J) three plasma metabolite modules, (K) Relation of AT(N) framework-related modules with AD PRS (with and without *APO* 603 of the AT(N) framework with (A-C) three CSF protein modules, (D-G) four plasma protein modules,
604 (H-J) three plasma metabolite modules, (K) Relation of AT(N) framework-related modules with AD 604 (H-J) three plasma metabolite modules, (K) Relation of AT(N) framework-related modules with AD PRS (with and without APOE region) at two thresholds (PT=5x10-8 605 & 0.1); red and blue links denoted 606 positive and negative correlations, respectively. CSF, cerebrospinal fluid; SNAP, Suspected Non-
607 Alzheimer Pathology. 607 Alzheimer Pathology.

Fronteins/metabolites from three CSF protein modules (M1 turquoise, M2 blue and M4 yellow), four

plasma protein modules (M2 blue, M3 brown, M4 yellow and M8 pink), and three plasma metabolite

modules (M4 yellow, M5 gree 609 proteins/metabolites from three CSF protein modules (M1 turquoise, M2 blue and M4 yellow), four
610 plasma protein modules (M2 blue, M3 brown, M4 yellow and M8 pink), and three plasma metabolite 611 modules (M4 yellow, M5 green and M3 brown); red, blue, light red and light blue squares denoted 612 positive association at FDR level (pFDR<0.05), negative association at FDR level (pFDR<0.05), positive
613 association at nominal level (p<0.05, pFDR>0.05), and negative association at nominal level (p<0.05, 613 association at nominal level (p<0.05, pFDR>0.05), and negative association at nominal level (p<0.05, 614 pFDR>0.05), respectively. (B) Partial correlation network selected for hub metabolites/proteins, 614 pFDR>0.05), respectively. (**B) Partial correlation network selected for hub metabolites/proteins,**
615 genetic factors, and MCI conversion. PRS, polygenic risk score; MCI, mild cognitive impairment.
615 genetic factor genetic factors, and MCI conversion. PRS, polygenic risk score; MCI, mild cognitive impairment.

A

B

Rap1 signaling pathway Axon guidance

Turquoise module

C

D

"А"

 $^{\prime\prime}$ T"

 $^{\prime\prime}$ N $^{\prime\prime}$

 $''V''$

 \mathbf{u}_{\vert}

 $^{\prime\prime}$ C"

Height

Blue module

Rap1 signaling pathway -Ras signaling pathway Focal adhesion 1 PI3K-Akt signaling pathway -Human papillomavirus infection -MAPK signaling pathway -Pathways in cancer-JAK-STAT signaling pathway -Metabolic pathways -

